The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Open accessAbstract
Purpose: Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous, with existing methods failing to consistently predict treatment failure. We examined the additional prognostic value of circulating tumor DNA (ctDNA) before and during therapy for predicting patient outcomes. Patients and Methods: We studied the dynamics of ctDNA from 217 patients treated at six centers, using a training and validation framework. We densely characterized early ctDNA dynamics during therapy using cancer personalized profiling by deep sequencing to define response-associated thresholds within a discovery set. These thresholds were assessed in two independent validation sets. Finally, we assessed the prognostic value of ctDNA in the context of established risk factors, including the International Prognostic Index and interim positron emission tomography/computed tomography scans. Results: Before therapy, ctDNA was detectable in 98% of patients; pretreatment levels were prognostic in both front-line and salvage settings. In the discovery set, ctDNA levels changed rapidly, with a 2-log decrease after one cycle (early molecular response [EMR]) and a 2.5-log decrease after two cycles (major molecular response [MMR]) stratifying outcomes. In the first validation set, patients receiving front-line therapy achieving EMR or MMR had superior outcomes at 24 months (EMR: EFS, 83% v 50%; P = .0015; MMR: EFS, 82% v 46%; P < .001). EMR also predicted superior 24-month outcomes in patients receiving salvage therapy in the first validation set (EFS, 100% v 13%; P = .011). The prognostic value of EMR and MMR was further confirmed in the second validation set. In multivariable analyses including International Prognostic Index and interim positron emission tomography/computed tomography scans across both cohorts, molecular response was independently prognostic of outcomes, including event-free and overall survival. Conclusion: Pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in aggressive lymphomas. These risk factors could potentially guide future personalized risk-directed approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationAxicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Self-citationChimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,099
Self-citationScherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8545 · Cited by 484
Self-citationRoschewski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E. S., Staudt, L. M., Lai, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70106-3 · Cited by 463
Self-citationChallenges of Guarantee-Time Bias
Giobbie-Hurder, A., Gelber, R. D., & Regan, M. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.5283 · Cited by 458
Maurer, M. J., Ghesquières, H., Jais, J.-P., Witzig, T. E., Haioun, C., Thompson, C. A., Delarue, R., Micallef, I. N., Peyrade, F., Macon, W. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5866 · Cited by 411
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Stiff, P. J., Unger, J. M., Cook, J. R., Constine, L. S., Couban, S., Stewart, D. A., Shea, T. C., Porcu, P., Winter, J. N., Kahl, B. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301077 · Cited by 343
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635169 · Cited by 337
Self-citationMoskowitz, C. H., Schöder, H., Teruya-Feldstein, J., Sima, C., Iasonos, A., Portlock, C. S., Straus, D., Noy, A., Palomba, M. L., O'Connor, O. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5942 · Cited by 326
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Rossi, D., Diop, F., Spaccarotella, E., Monti, S., Zanni, M., Rasi, S., Deambrogi, C., Spina, V., Bruscaggin, A., Favini, C., et al. (2017) · Blood · doi:10.1182/blood-2016-05-719641 · Cited by 256
Self-citationCottereau, A.-S., Lanic, H., Mareschal, S., Meignan, M., Vera, P., Tilly, H., Jardin, F., & Becker, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2825 · Cited by 188
Self-citationMeignan, M., Sasanelli, M., Casasnovas, R. O., Luminari, S., Fioroni, F., Coriani, C., Masset, H., Itti, E., Gobbi, P. G., Merli, F., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2705-y · Cited by 186
Self-citationLeonard, J. P., Kolibaba, K. S., Reeves, J. A., Tulpule, A., Flinn, I. W., Kolevska, T., Robles, R., Flowers, C. R., Collins, R., DiBella, N. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2784 · Cited by 186
Safar, V., Dupuis, J., Itti, E., Jardin, F., Fruchart, C., Bardet, S., Véra, P., Copie-Bergman, C., Rahmouni, A., Tilly, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2648 · Cited by 162
Self-citationChiappella, A., Martelli, M., Angelucci, E., Brusamolino, E., Evangelista, A., Carella, A. M., Stelitano, C. C., Rossi, G., Balzarotti, M., Merli, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30444-8 · Cited by 132
Shi, Q., Flowers, C. R., Hiddemann, W., Marcus, R. E., Herold, M. J., Hagenbeek, A., Kimby, E. K., Höchster, H. S., Vitolo, U., Peterson, B. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8651 · Cited by 120
Casasnovas, O., Ysebaert, L., Thiéblemont, C., Bachy, E., Feugier, P., Delmer, A. J., Tricot, S., Gabarre, J., André, M. P. E., Fruchart, C., et al. (2017) · Blood · doi:10.1182/blood-2017-02-766691 · Cited by 100
Self-citationHigh-throughput sequencing for noninvasive disease detection in hematologic malignancies
Scherer, F., Kurtz, D. M., Diehn, M., & Alizadeh, A. A. (2017) · Blood · doi:10.1182/blood-2017-03-735639 · Cited by 82
Self-citationDynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma
Roschewski, M. J., Staudt, L. M., & Wilson, W. H. (2016) · Blood · doi:10.1182/blood-2016-03-635219 · Cited by 75
Self-citationSwinnen, L. J., Li, H., Quon, A. S. W., Gascoyne, R. D., Hong, F., Ranheim, E. A., Habermann, T. M., Kahl, B. S., Horning, S. J., & Advani, R. H. (2015) · British Journal of Haematology · doi:10.1111/bjh.13389 · Cited by 58
Self-citationHertzberg, M., Gandhi, M. K., Trotman, J., Butcher, B., Taper, J., Johnston, A., Gill, D. S., Ho, S., Cull, G., Fay, K. C., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.154039 · Cited by 57
Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma
Moffitt, A. B., & Davé, S. S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7603 · Cited by 50
Cited by
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600
Self-citationSusanibar‐Adaniya, S., & Barta, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26151 · Cited by 388
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00981-w · Cited by 374
Self-citationDetection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Sequencing-based measurable residual disease testing in acute myeloid leukemia
Yoest, J. M., Shirai, C. L., & Duncavage, E. J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00249 · Cited by 48
Metadata
- Authors
- Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Advani, R. H., Levy, R., Newman, A. M., Dührsen, U., Hüttmann, A., Meignan, M., Casasnovas, R.-O., Westin, J. R., Roschewski, M., Wilson, W. H., Gaidano, G., Rossi, D., Diehn, M., & Alizadeh, A. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-10-01
- Volume
- 36
- Issue
- 28
- Pages
- 2845-2853
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2888203943
- Cited by
- 497
- References
- 30
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.